A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic
about
Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesSynthetic self-adjuvanting glycopeptide cancer vaccinesTotal synthesis of glycosylated proteinsSynthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.Two-step functionalization of oligosaccharides using glycosyl iodide and trimethylene oxide and its applications to multivalent glycoconjugates.Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions.Synthesis of granulocyte-macrophage colony-stimulating factor as homogeneous glycoforms and early comparisons with yeast cell-derived material.Integrating ReSET with glycosyl iodide glycosylation in step-economy syntheses of tumor-associated carbohydrate antigens and immunogenic glycolipidsAntibody recognition of carbohydrate epitopes†.Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale.Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics.Sialic acids in biological and therapeutic processes: opportunities and challenges.Recent advances in the molecular design of synthetic vaccines.Bioactive clusters promoting cell penetration and nucleic acid complexation for drug and gene delivery applications: from designed to self-assembled and responsive systems.A rationally designed peptidomimetic biosensor for sialic acid on cell surfaces.Antibodies against mucin-based glycopeptides affect Trypanosoma cruzi cell invasion and tumor cell viability.Immunological evaluation of the entirely carbohydrate-based Thomsen-Friedenreich - PS B conjugate.Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody.Automated assembly of oligosaccharides containing multiple cis-glycosidic linkages.Recent progress in antitumoral synthetic vaccines.Serine versus threonine glycosylation with α-O-GalNAc: unexpected selectivity in their molecular recognition with lectins.Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides.Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate.Enzyme-catalyzed Ag Growth on Au Nanoparticle-assembled Structure for Highly Sensitive Colorimetric Immunoassay.Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment.
P2860
Q26746887-62D3061C-B4E6-4F75-899B-37ACB7B4EC43Q26777837-C6774CD9-99AC-406A-8315-71A8AF94DDFFQ28083496-EB0AC5AF-C108-4B55-B7B0-2D749FB7D9FCQ35030845-3A7E9D46-251A-4362-B673-5712CBE231D3Q35835615-C8413A13-717A-4D16-8520-03F4D18D85A2Q37581781-689FD21A-9742-4A79-A9A6-7B2CD0D01A85Q37612674-0FAC72F7-BDEA-4956-85F0-BB36123BFC6AQ37701761-E762643F-26AE-4894-A7B4-7FB719A7B13AQ37840398-3C60E0DA-A17B-4D23-AC93-CE2CA524CF45Q38202512-E224D060-F079-4709-AA94-87C6F81C3CD9Q38533442-8FCD3469-EEC3-4E63-91FE-BCDFA393CD17Q38618833-47D052F3-D449-41D9-977F-42D9A66AD617Q38639938-8A40BC4A-8ED8-418A-9986-EA5CC2ADA26DQ38722141-D6CA2A25-6301-4D24-8BCC-1557D14FCC9CQ38887946-6B7653AC-A35B-4471-A16B-373A1F118950Q38985680-315923A0-7ACB-42F4-8D35-85DF39A3379AQ39935587-6AE36C62-C29C-45ED-92D0-15D883754A83Q40789473-EFE47961-9C84-433A-877E-B1358943D98EQ41107317-BFB2F087-C61D-452A-8A48-0C9303B41881Q43007810-9C1357E3-CD24-4C38-8B7C-60AC5F455279Q43856190-723B5282-B963-4BFE-845A-4469C5205E36Q47902181-BFA58E6F-8E9D-452C-A61B-2886AAA2FB15Q48169265-1ECB1191-94F6-4096-BD2F-95BEA1D577D0Q48246161-32549558-6B32-4A91-BBEA-5EF8875367ECQ55215867-D07B3CDB-C2C5-49BE-8FC8-A3F2DD45D142Q55322543-7F6F08E2-EF07-4792-8CFD-5A9C837BB312
P2860
A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A vision for vaccines built fr ...... m the laboratory to the clinic
@en
A vision for vaccines built fr ...... the laboratory to the clinic.
@nl
type
label
A vision for vaccines built fr ...... m the laboratory to the clinic
@en
A vision for vaccines built fr ...... the laboratory to the clinic.
@nl
prefLabel
A vision for vaccines built fr ...... m the laboratory to the clinic
@en
A vision for vaccines built fr ...... the laboratory to the clinic.
@nl
P2860
P356
P1476
A vision for vaccines built fr ...... m the laboratory to the clinic
@en
P2093
Rebecca M Wilson
Samuel J Danishefsky
P2860
P304
14462-14472
P356
10.1021/JA405932R
P407
P577
2013-09-18T00:00:00Z